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Background:  Sulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent 
studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ), 
one of the nuclear receptors. In this study, we investigated the effects of sulfonylurea on PPARγ transcriptional activity and on 
the glucose uptake via PPARγ.
Methods:  Transcription reporter assays using Cos7 cells were performed to determine if specific sulfonylureas stimulate PPARγ 
transactivation. Glimepiride, gliquidone, and glipizide (1 to 500 µM) were used as treatment, and rosiglitazone at 1 and 10 µM was 
used as a control. The effects of sulfonylurea and rosiglitazone treatments on the transcriptional activity of endogenous PPARγ 
were observed. In addition, 3T3-L1 adipocytes were treated with rosiglitazone (10 µM), glimepiride (100 µM) or both to verify 
the effect of glimepiride on rosiglitazone-induced glucose uptake.
Results:  Sulfonylureas, including glimepiride, gliquidone and glipizide, increased PPARγ transcriptional activity, gliquidone be-
ing the most potent PPARγ agonist. However, no additive effects were observed in the presence of rosiglitazone. When rosigli-
tazone was co-treated with glimepiride, PPARγ transcriptional activity and glucose uptake were reduced compared to those after 
treatment with rosiglitazone alone. This competitive effect of glimepiride was observed only at high concentrations that are not 
achieved with clinical doses.
Conclusion:  Sulfonylureas like glimepiride, gliquidone and glipizide increased the transcriptional activity of PPARγ. Also, 
glimepiride was able to reduce the effect of rosiglitazone on PPARγ agonistic activity and glucose uptake. However, the competi-
tive effect does not seem to occur at clinically feasible concentrations.
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INTRODUCTION
Insulin resistance is a characteristic feature in the pathogenesis 
of type 2 diabetes mellitus [1-3]. Thiazolidinediones (TZDs) 
are a class of antidiabetic agents that improve peripheral insu-
lin resistance and lead to lower fasting and postprandial glu-
cose levels, as well as circulating insulin levels [3]. TZDs bind 
to peroxisome proliferator-activated receptor γ (PPARγ) with-
in the cell nucleus and activate the transcription of several 
specific genes which result in glycemic control, increase in 
high density lipoprotein, reduction of triglyceride, free fatty 
acids and small, dense low density lipoprotein, inhibition of 
tumoral angiogenesis, anti-inflammatory effects and adipose 
cell differentiation [4,5]. PPARγ is a member of the nuclear re-
ceptor superfamily and functions as a heterodimer with reti-
noid X receptors (RXRs) [4,6]. The C-terminal region of 
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PPARγ, called ligand binding domain, is dimerized with RXR 
and contains the major transcriptional activation domain, 
termed the activation-function 2 (AF2) domain. This region is 
important for the docking of coactivators and forms a ligand-
binding pocket through conformational change [4]. Also, the 
N-terminal of PPARγ has transcriptional activity and leads to 
diverse biological actions [4,7]. 
  Various substances have been suggested to be natural ligands 
for PPARγ, such as fatty acids and eicosanoids [8], components 
of oxidized low-density lipoproteins [9] and nitrolinoleic acid 
[10,11]. Additionally, some synthetic compounds, including 
TZDs, some non-steroidal anti-inflammatory drugs [12] and 
telmisartan, an angiotensin II receptor antagonist [13,14], 
showed a partial agonistic effect to PPARγ. Recently, investiga-
tors demonstrated that some antidiabetic sulfonylureas, whose 
main mechanism in glycemic control is to stimulate insulin 
secretion by binding to the sulfonylurea receptor of pancreatic 
β-cells, played roles as PPAR agonists [15-18].
  In the present work, we compared PPARγ activating prop-
erties of sulfonylureas to those of rosiglitazone and also inves-
tigated their effects on PPARγ activity when combined with 
rosiglitazone.
METHODS
Materials
Rosiglitazone was purchased from Cayman Chemical (Ann 
Arbor, MI, USA), gliquidone from Apin Chemicals (Abing-
don, UK), and glipizide from Sigma-Aldrich (Louis, MO, USA). 
Glimepiride was a kind gift from the Handok Co. (Seoul, Ko-
rea). Agents were dissolved in dimethyl sulfoxide (Sigma, St. 
Louis, MO, USA).
Cell culture
COS7 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS). 3T3-
L1 preadipocytes were cultured in DMEM with 10% calf se-
rum. Two days after 3T3-L1 cells had reached confluence, dif-
ferentiation was induced by treating the cells with 10% FBS-
supplemented DMEM containing 0.5 nM 3-isobutyl-1-meth-
ylxanthine (IBMX), 0.25 µM dexamethasone and 5 µg/mL in-
sulin for 48 hours. Cells were refed in DMEM with 10% FBS 
and 1 µg/mL insulin for the following two days and were then 
maintained in DMEM with 10% FBS for the following four 
days. 
Construction of plasmids
The Gal4 DNA binding domain fused expression vectors en-
coding the deletion mutant of mouse PPARγ2 were prepared 
by subcloning the corresponding cDNAs into a pM vector. 
The cDNAs encoding the full-length DNA (WT, amino acid 
1-505), the activation function-1 domain (AF1, amino acid 
1-138), the ligand binding domain-deleted construct (∆LBD, 
amino acid 1-311) and only the ligand binding domain (LBD, 
amino acid 203-505) of the mouse PPARγ type 2 were gener-
ated using polymerase chain reaction with oligonucleotide 
primers. Primer sets were as follows: WT, AF1, and ∆LBD 
sense primer, 5′-agt cga ctg ggt gaa act ctg gga gat tc-3′; LBD 
sense primer, 5′- atg tcg acg gat gtc tca caa tgc cat cag g-3′; WT 
and LBD antisense primer, 5′-ggt cta gac ggg tgg gac ttt cct gc-
3′; AF1 antisense primer, 5′-cct cta gac tca atg gcc atg agg-3′; 
∆LBD antisense primer, 5′-att cta gat tga aaa att cgg atg gcc ac-
3′. The amplicons were ligated into the pM vector containing 
the Gal4 DNA binding domain at the N-terminal using the SalI 
and XbaI sites. Gal4-responsive tk-Luc reporters (Gal4 tk-Luc) 
were used to evaluate the transcriptional activity of PPARγ, 
and β-galactosidase (pCMV-β-gal) was used to normalize the 
transient transfection efficiency.
Transient transfection, treatment and reporter assay
COS7 cells in 12-well plates were transfected with Gal4 tk-Luc 
(0.1 µg), pCMV-β-gal (0.1 µg) and pM-PPARγ constructs 
(0.03 µg) using LipofectAMIN Plus (Invitrogen, Carlsbad, CA, 
USA). Cells were incubated in DMEM supplemented with 10% 
FBS and were treated with glimepiride, gliquidone, glipizide 
and rosiglitazone at the indicated doses for 24 hours. In order 
to identify the concentration-dependent activation of PPARγ 
by sulfonylureas, 1, 10, and 100 µM of glimepiride and 1, 10, 
and 30 µM of gliquidone were used. Luciferase activity was 
determined using the Luciferase Assay System Kit (Promega, 
Madison, WI, USA) and Lumat LB9507 (Berthold, Bad Wild-
bad, Germany). Luciferase activity was normalized according 
to β-galactosidase activity. 
Glucose uptake
3T3-L1 adipocytes were treated with rosiglitazone (10 µM), 
glimepiride (100 µM) or both for 48 hours. After the addition 
of insulin (100 nM) to the medium for 30 minutes, cells were 
washed with salt-HEPES buffer (4.7 mM KCl, 130 mM NaCl, 
1.25 mM CaCl2, 2.5 mM NaH2PO4, 1.2 mM MgSO4, and 10 
mM HEPES). Cells were incubated in salt-HEPES buffer con-342
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taining 0.2 µCi of [
3H]deoxyglucose for 15 minutes. Uptake was 
terminated via five rapid washes with cold phosphate-buffered 
saline (PBS). Cells were lysed by 0.5N NaOH and neutralized 
by HCl. The radioactivity was determined using liquid scintil-
lation counting in a β-counter and normalized according to 
total protein level.
Statistics
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. The data are expressed as mean±standard 
error. The differences between the means were calculated us-
ing the Mann-Whitney U-test. A P value less than 0.05 denot-
ed the presence of a statistically significant difference.
RESULTS
PPARγ transcriptional activity by sulfonylureas
Transcription reporter assays were used to determine the ef-
fects of sulfonylureas including glimepiride, gliquidone, and 
glipizide on the transcriptional activity of PPARγ. Each sulfo-
nylurea was tested at the following concentrations: glimepiride, 
1, 10, 100, and 300 µM; gliquidone, 1, 10, 30, and 100 µM; glipi-
zide, 1, 10, 100, 300, and 500 µM and rosiglitazone, 1 and 10 
µM. We obtained the peak concentration at which glimepiride 
and gliquidone induced the highest transcriptional activity; 
gliquidone, 30 µM and glimepiride, 100 µM. Glipizide reached 
saturation at concentrations greater than 500 µM, therefore, 
tests were performed at lower concentrations, although we did 
not obtain the peak value. All agents except glipizide signifi-
cantly increased PPARγ agonistic activity at the indicated con-
centrations. Glimepiride and gliquidone increased PPARγ 
transcriptional activity at 1 µM, by 3-4 times at 10 µM, and by 
nearly ten times at higher concentrations. All of these increas-
es were statistically significant, although they were lower than 
that of rosiglitazone. In the case of glipizide, no agonistic effect 
at 1 µM was observed, but there was a mild effect at concentra-
tions greater than 10 µM (Fig. 1).
Target region of sulfonylureas in PPARγ
In order to identify the target domain of sulfonylureas in 
PPARγ, we prepared three constructs from wild type PPARγ 
(pM-WT). One was the AF1 region (pM-AF1), another lacked 
the ligand binding domain (pM-ΔLBD), and the other was the 
ligand binding domain (pM-LBD) (Fig. 2A). The increment of 
PPARγ transcriptional activity caused by sulfonylureas disap-
peared when pM-AF1 or pM-ΔLBD was transfected, regard-
less of the type of sulfonylurea, whereas it was maintained in 
presence of pM-LBD (Fig. 2B). Based on these observations, it 
was suggested that the effect of sulfonylureas, like thiazolidin-
ediones, on the PPARγ transcriptional activity involves bind-
ing to the ligand binding domain of PPARγ.
Combinational treatment of sulfonylureas and 
rosiglitazone
We examined the effects of rosiglitazone in addition to each 
sulfonylurea on the PPARγ transcriptional activity. When 
glimepiride (100 μM), gliquidone (10 μM), or glipizide (100 
μM) was administered with rosiglitazone (1 μM), sulfonylureas 
did not provide any additive effects on the PPARγ transcrip-
tional activity of the cells compared to that achieved with rosi-
glitazone alone. Interestingly, glimepiride reduced the effect of 
rosiglitazone on PPARγ transcriptional activity by about 50 
percent, which was statistically significant, while gliquidone 
and glipizide showed no depletive influence (Fig. 3A). 
  Because glimepiride and gliquidone were more effective than 
was glipizide for stimulation of PPARγ transcriptional activity, 
we investigated the effects of combination treatments with 
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Fig. 1.  Peroxisome proliferator-activated receptor γ (PPARγ) 
transcriptional activity by thiazolidinediones (rosiglitazone) 
and sulfonylureas (glimepiride, gliquidone, and glipizide). Cos 
7 cells were transfected with Gal4 tk-Luc, pCMV-β-gal, and 
pM-PPARγ and treated with rosiglitazone (1 to 10 μM), 
glimepiride (1 to 300 μM), gliquidone (1 to 100 μM) or glipi-
zide (1 to 500 μM) for 24 hours. β-galactosidase activity was 
used for normalization of luciferase activity. The luciferase ac-
tivity of the cells treated with DMSO was set to 1, and the oth-
ers were expressed as relative values. Data represent the mean± 
standard error of the mean (SEM) (n=3).343
Sulfonylureas and PPAR γ 
Diabetes Metab J 2011;35:340-347 http://e-dmj.org
rosiglitazone in the presence of different sulfonylurea concen-
trations using glimepiride and gliquidone. In the combined 
treatment, glimepiride inhibited the effect of rosiglitazone in a 
dose-dependent manner. Under constant rosiglitazone treat-
ment at a dose of 1 µM, when treated with glimepiride 1 µM, 
luciferase activity showed no change compared to that of the 
control; at 10 µM, luciferase activity seemed to be lowered, but 
the effect was not statistically significant. In contrast, when 
combined with 100 µM glimepiride, the reduction in activity 
was significantly greater; gliquidone did not show any differ-
pM-WT
1 139 203   279 505 a.a.
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Fig. 2.  Target regions of sulfonylureas in peroxisome proliferator-activated receptor γ (PPARγ). (A) Schematic diagram of 
PPARγ constructs. Three constructs from wild type PPARγ (pM-WT) were prepared. pM-ΔLBD lacked the ligand binding do-
main, pM-AF1 carried only the AF1 region and pM-LBD had only the ligand binding domain. (B) Transcriptional activity ac-
cording to PPARγ construct. pM-WT, pM-AF1, pM-ΔLBD, or pM-LBD were cotransfected with Gal4 tk-Luc and pCMV-β-gal 
into COS7 cells. Cells were treated with glimepiride, gliquidone, glipizide or rosiglitazone at indicated doses for 24 hours. The lu-
ciferase activity of the cells treated with DMSO after overexpression of PPARγ wild type or its deletions, respectively, was set to 1, 
and other activities were expressed as relative values. Data represent the mean±standard error of the mean (SEM) (n=5). 
aP<0.05.
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Fig. 3.  Combination treatments of thiazolidinediones and sulfonylurea. (A) Combination treatments of thiazolidinediones and 
sulfonylurea. To examine the effects of rosiglitazone in combination with each sulfonylurea on the peroxisome proliferator-acti-
vated receptor γ (PPARγ) transcriptional activity, COS7 cells were transfected with Gal4 tk-Luc, pCMV-β-gal, and pM or pM-
PPARγ and treated with glimepiride (100 μM), gliquidone (10 μM), or glipizide (100 μM) plus rosiglitazone (1 μM). Data repre-
sent the mean±standard error of the mean (SEM) (n=4). 
aP<0.05. (B) Combination treatment according to sulfonylurea dose. 
Cos 7 cells were transfected with Gal4 tk-Luc, pCMV-β-gal, or pM-PPARγ and treated with rosiglitazone, glimepiride or gliqui-
done at the indicated doses for 24 hours. Data represent mean±standard error of the mean (SEM) (n=4). 
aP<0.05.
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ence in luciferase activity at any concentration, although gliq-
uidone was similar or more effective than glimepiride at the 
indicated dose (Fig. 3B).
Effect of glimepiride on glucose uptake by 
thiazolidinediones
We evaluated the effects of rosiglitazone or glimepiride mono-
therapy and the combined therapy of the two on insulin-stim-
ulated glucose uptake in adipocytes. Each monotherapy and 
the combination therapy produced an increase in glucose up-
take. However, the glucose uptake in co-treatment was less than 
that of rosiglitazone monotherapy (Fig. 4). It is supposed that 
the effect of rosiglitazone on glucose uptake was inhibited by 
glimepiride, and this seems to be related to the effect of PPARγ 
transcriptional activity.
DISCUSSION
There has been increasing interest in the effects of sulfonylurea 
on PPARγ transcriptional activity. The major findings of our 
experiments showed that sulfonylureas increased PPARγ tran-
scriptional activity, and glimepiride showed dose-dependent 
competition with rosiglitazone for PPARγ, whereas gliquidone 
and glipizide did not exhibit competitive behaviors. 
  It has been reported that some sulfonylureas enhance PPARγ 
transcriptional activity and, thus, target both sulfonylurea re-
ceptors in the membranes of pancreatic β-cells and PPARγ in 
the nuclei of adipocytes [15-18]. Arrault et al. [17] explored 
the PPARγ-activating properties of a series of eight sulfonyl-
ureas using transfection experiments with 293T cells and rosi-
glitazone as a reference PPARγ agonist. They found that sec-
ond generation sulfonylureas, including glimepiride, gliqui-
done, and glibenclamide, stimulated PPARγ-activating prop-
erties, but first generation agents, such as tolbutamide, chlor-
propamide, tolazamide and gliclazide, in addition to the sec-
ond generation agent glipizide, did not [17]. Their findings 
were consistent with our results and with previously published 
data by Fukuen et al. [15], with the exception of the glipizide 
results. In the present study and the work of Fukuen et al. [15], 
glipizide increased the PPARγ transcriptional activity. 
  Glipizide is known to exhibit a slightly different binding 
mode compared to those of glimepiride, gliquidone and glib-
enclamide [17,18]; glipizide binds PPARγ more weakly than 
do the others. The strength of this binding is determined by 
the hydrogen bonds (H-bond) formed between the docked li-
gand and the amino acids in PPARγ which form the binding 
pocket within the active site. The H-bonding pattern of glipi-
zide is different from those of these other compounds [17]. 
Compared to glimepiride and gliquidone, which form more 
than two hydrogen bonds with the PPARγ ligand binding 
pocket, glipizide forms only one hydrogen bond and, thus, 
functions as a weak binder [17]. In this respect, glipizide showed 
weaker PPARγ agonistic activity than did the other second 
generation sulfonylureas. Additionally, glipizide may activate 
PPARγ in a tissue-specific manner; it showed PPARγ agonistic 
activity in CV-1 cells [18] and Cos7 cells but not in 293T cells 
[17]. 
  Other authors have observed PPARγ agonistic activity of 
glimepiride at 1 and 10 μM [15,16] similar to our results. The 
mean maximal plasma concentration (Cmax) values for glimepiri-
de can reach 1 μM when patients are treated with the suggest-
ed maximum daily does of 8 mg [19,20]. For gliquidone, when 
treated with a 30 mg dose, Cmax is 1.2 μM, with a range from 0.2 
to 0.4 μM [21]. In our experiment, gliquidone showed a PPARγ 
agonistic effect even when treated with 1 μM. Based on this result, 
glimepiride and gliquidone seem to be able to activate PPARγ 
at pharmacological concentrations. In addition, glimepiride, a 
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Fig. 4.  Effects of glimepiride on rosiglitazone-induced glu-
cose uptake. On day 8 of differentiation, 3T3-L1 adipocytes 
were treated with rosiglitazone (10 μM), glimepiride (100 μM) 
or both for 48 hours and with insulin for 30 minutes. Glucose 
uptake was measured using [
3H]-deoxyglucose scintillation 
counting. The glucose uptake value of untreated cells was set 
to 100, and the others were relative values. Data represent the 
mean±standard error of the mean (SEM) (n=3). 
aP<0.05, 
bP<0.05 compared to the control.345
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third generation sulfonylurea, demonstrated the ability to im-
prove insulin sensitivity in a human study [22]. Insulin resis-
tance estimated using homeostatic model assessment-insulin 
resistance (HOMA-IR) was significantly reduced in subjects 
with type 2 diabetes who took glimepiride, although glycemic 
control measured using HbA1c was unchanged [22]. Also, 
gliquidone was shown to be as potent as pioglitazone for in-
ducing PPARγ target gene expression [18]. 
  In the case of glipizide, which was able to weakly activate 
PPARγ at a dose of 10 μM in our experiment, Cmax values are 
1.0±0.3 μM in subjects treated with a 5 mg dose [23]. Even in 
subjects administered the maximum daily dose of 40 mg, the 
concentration able to induce PPARγ agonistic activity is not 
achieved.
  One of the novel findings of this study was that glimepiride 
reduced the effect of rosiglitazone at high concentrations, but 
gliquidone or glipizide did not. In our results, glimepiride sig-
nificantly inhibits the effect of rosiglitazone on PPARγ tran-
scriptional activity in a dose-dependent manner, and cell via-
bility was not affected in the tested dose range (data not shown). 
Our results are consistent with the results of a previous report 
[15].
  Fukuen and co-workers performed competitive binding as-
says using full-length PPARγ2 and [
3H] rosiglitazone. The 
concentration-dependent displacement of [
3H] rosiglitazone 
by glimepiride was observed; therefore, they concluded that 
glimepiride is in competition with rosiglitazone and activates 
PPARγ through direct association and could be considered as 
a partial agonist for PPARγ [15]. In the case of gliquidone, al-
though it had stronger agonistic effects than did glimepiride, it 
did not reduce the effect of rosiglitazone even at 30 μM, the 
highest concentration tested.
  The explanation for these differences is not clear. It is known 
that the TZD head-group forms hydrogen bonds with the 
PPARγ residues which form the loop structure within the ac-
tive site [17,24]. Glimepiride generated H-bonds with Ser289, 
Ser342, and the Gly284, whereas gliquidone interacted with 
Gln286 and Ser342 [17]. Rosiglitazone and glimepiride shared 
Ser289, but gliquidone did not. Glipizide, which showed no 
competitive effect against rosiglitazone, was a weak binder com-
pared to the other sulfonylureas. Further investigation about the 
exact mechanism is needed. 
  Though glimepiride inhibits the effect of rosiglitazone at a 
dose of 100 μM, competition between glimepiride and rosigli-
tazone is not expected in clinical practice since Cmax can be 1 
μM at the maximum daily dose of glimepiride (8 mg).
  Although sulfonylurea drugs produce a glucose-lowering 
effect by stimulating insulin secretion in the pancreatic β-cells 
in an ATP-sensitive, K
+ channel-dependent manner; they have 
also been proposed to have peripheral effects as an insulin 
sensitizer [22,25-27]. Glimepiride, the most recently developed 
sulfonylurea agent, induces glucose uptake in extrapancreatic 
tissue not only by increasing insulin secretion in the pancreat-
ic β-cells, but also by stimulating GLUT1 and GLUT4 translo-
cations in both normal and insulin-resistant states, indepen-
dent of insulin [28,29]. In addition, although a peroxisome 
proliferator response element (PPRE) site in the GLUT4 gene 
has not been identified [30,31], PPARγ appears to increase 
GLUT4 [30-33]. In spite of that, the precise underlying mech-
anism through which sulfonylureas and thiazolidinediones 
increase glucose uptake in extrapancreatic tissues has not been 
verified. It is suggested that PPARγ, activated by certain sulfo-
nylureas, induces GLUT4 to be inserted into the plasma mem-
brane through direct interaction of glimepiride with PPARγ 
molecules or through another indirect mechanism involving a 
definite signaling pathway that leads to increased glucose up-
take. 
  Recently, the Food and Drug Administration (FDA) limited 
the use of rosiglitazone due to increased cardiovascular risk 
[34]. Sulfonylureas are also known to increase the risk of car-
diovascular events [35,36], mostly attributed to their effect on 
myocardial ATP-sensitive K
+ channels. Because some sulfo-
nylureas activate PPARγ, one cannot exclude the possibility 
that increasing PPARγ activity might also contribute to sulfo-
nylurea’s cardiovascular effect. 
  Our findings that sulfonylureas induce PPARγ transcrip-
tional activity at clinically relevant concentrations will be help-
ful for understanding the mechanisms of sulfonylureas in the 
treatment of subjects with type 2 diabetes mellitus.
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